Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR T790M”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT02094261
What this trial is testing

Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours

Who this might be right for
Non Small Cell Lung Cancer
AstraZeneca 210
Testing effectiveness (Phase 2)UnknownNCT05767866
What this trial is testing

Assessing an Oral EGFR Inhibitor,YK-209A in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR

Who this might be right for
TreatmentTreatment Side Effects
Suzhou Puhe Pharmaceutical Technology Co., LTD 160
Post-approval studies (Phase 4)Active Not RecruitingNCT04413201
What this trial is testing

AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients with EGFRmutated/T790M Mutation Negative Nonsquamous NSCLC

Who this might be right for
Non-squamous NSCLC
Michael Hopp 34
Testing effectiveness (Phase 2)UnknownNCT05458726
What this trial is testing

Correlation Between Efficacy of Osimertinib and EGFR T790M Status and Ratio Via ddPCR in NSCLC

Who this might be right for
EGFR T790MOsimertinibNon-small Cell Lung Cancer+1 more
Peking Union Medical College 80
Testing effectiveness (Phase 2)Study completedNCT03386955
What this trial is testing

BPI-7711 Capsule in Patients With EGFR Mutation T790M Positive Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Beta Pharma Shanghai 215
Testing effectiveness (Phase 2)UnknownNCT04338243
What this trial is testing

Glumetinib Combined With Osimertinib in the Treatment of Relapsed and Metastatic Non-small Cell Lung Cancer Patients Who Failed to Receive EGFR Inhibitors

Who this might be right for
Negative T790M Mutation and Met Amplification
Haihe Biopharma Co., Ltd. 70
Early research (Phase 1)Study completedNCT03516214
What this trial is testing

EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR Mutations

Who this might be right for
Bronchial Neoplasms
University of Cologne 18
Testing effectiveness (Phase 2)Study completedNCT02841579
What this trial is testing

Osimertinib (AZD9291) in First-line Locally Advanced or Metastatic NSCLC Patients With EGFR and EGFR T790M

Who this might be right for
Non-Small Cell Lung Cancer
MedSIR 22
Not applicableStudy completedNCT02418234
What this trial is testing

T790M Mutation on ctDNA in Patients With NSCLC After EGFR-TKI Failure

Who this might be right for
Non-small Cell Lung Cancer Stage IIINon-Small-Cell Lung Cancer Metastatic
First People's Hospital of Hangzhou 314
Early research (Phase 1)Ended earlyNCT02448251
What this trial is testing

Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010MA in Advanced Non Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
ACEA Therapeutics, Inc. 28
Not applicableUnknownNCT05314296
What this trial is testing

Osimertinib for Russian EGFR T790M Mutation-positive NSCLC Patients Who Progressed on or After EGFR TKI Therapy

Who this might be right for
Non Small Cell Lung CancerT790MEGFR Gene Mutation
N.N. Blokhin National Medical Research Center of Oncology 70
Not applicableStudy completedNCT03219970
What this trial is testing

Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.

Who this might be right for
Non-small Cell Lung Cancer
AstraZeneca 156
Large-scale testing (Phase 3)Study completedNCT02151981
What this trial is testing

AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Anticancer Treatment
AstraZeneca 421
Not applicableActive Not RecruitingNCT01754025
What this trial is testing

INHERIT EGFR - Studying Germline EGFR Mutations

Who this might be right for
Lung Cancer
Dana-Farber Cancer Institute 121
Not applicableEnded earlyNCT03053297
What this trial is testing

Observational Study of Patients With Locally Advanced or Metastatic NSCLC (Non-Small Cell Lung Cancer)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
AstraZeneca 89
Testing effectiveness (Phase 2)Ended earlyNCT02192697
What this trial is testing

An Open Study of ASP8273 in Patients With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations

Who this might be right for
Non-small Cell Lung Cancer
Astellas Pharma Inc 124
Testing effectiveness (Phase 2)Ended earlyNCT02147990
What this trial is testing

Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Clovis Oncology, Inc. 318
Early research (Phase 1)Active Not RecruitingNCT03333343
What this trial is testing

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

Who this might be right for
EGFR-mutant Non-small Cell Lung Cancer
Novartis Pharmaceuticals 105
Large-scale testing (Phase 3)UnknownNCT02972333
What this trial is testing

Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790M

Who this might be right for
EGFR-TKI Resistant MutationNonsmall Cell Lung CancerAZD9291+1 more
Shandong Cancer Hospital and Institute 150
Testing effectiveness (Phase 2)UnknownNCT02274337
What this trial is testing

Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of AC0010 in Advanced Non Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Sun Yat-sen University 100
Next Page